GPX7 and glioblastoma: Curiously, a recent pathway-based classification suggested that GBM tumors classified as mitochondrial exhibited marked vulnerability to inhibitors of oxidative phosphorylation (OXPHOS), which increased intracellular ROS and sensitivity to radiotherapy, thus strengthening the potential application of synergic GPX7 and OXPHOS inhibition in mitochondrial subtype to boost antitumor and immune responses141.